Introduction: Febrile neutropenia (FN) induced by chemotherapy (ChT) arises until 6 weeks after the last cycle, usually between 5 and 10 days post-ChT. Infection risk is 20%–30%. It is difficult to stratify patients with low risk of complications
Search Results
BPI19-010: Febrile Neutropenia Induced by Chemotherapy: Impact of Risk Re-Stratification
David da Silva Dias, Catarina Jorge, Mafalda Baptista, Ana Júlia Arede, Paulo Luz, Tânia Madureira, and Beatriz Gosalbez
QIM19-129: Utilization of Electronic Medical Record to Improve Outcomes in the Treatment of Febrile Neutropenia
Anna M. Gibson and Claire Sutherby
Introduction: Chemotherapy-induced febrile neutropenia is a medical emergency. Delays in time to appropriate broad spectrum antibiotic therapy significantly increase morbidity and mortality. The purpose of this project is to improve outcomes in
Timing of Initial Antibiotic Treatment for Febrile Neutropenia in the Emergency Department: The Need for Evidence-Based Guidelines
Demetrios N. Kyriacou, Borko Jovanovic, and Olga Frankfurt
several studies that illustrate the delayed times to initial antibiotic treatment for adults with FN in EDs Table 1 Current Guidelines for Timing of Initial Antibiotic Treatment of Adult Patients With Febrile Neutropenia worldwide, indicating
Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules
Betsy L. Althaus
-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors . Eur J Cancer 2006 ; 42 : 2433 – 2453 . 8. Scott SD Chrischilles EA Link BK . Days of prophylactic
Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao
Background Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy that can affect treatment by contributing to dose delays and reductions. 1 FN often requires hospitalization and incurs a significant healthcare
The Utility of Routine Chest Radiography in the Initial Evaluation of Adult Patients With Febrile Neutropenia Patients Undergoing HSCT
Deborah S. Yolin-Raley, Ibiayi Dagogo-Jack, Heidi B. Niell, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea III, and Brett E. Glotzbecker
Background Most patients treated with myeloablative conditioning regimens before hematopoietic stem cell transplantation (HSCT) develop neutropenic fevers in the pre-engraftment period because of profound neutropenia. 1 , 2 Fevers may signify
CLO19-051: CDK 4/6 Inhibitor-Associated Hematologic Toxicities and Febrile Neutropenia in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
Sriman Swarup, Anita Sultan, Somedeb Ball, Francis Mogollon-Duffo, Nimesh Adhikari, Yin M. Myat, Myo H. Zaw, Catherine Jones, and Kyaw Z. Thein
: MEDLINE, EMBASE databases, and meeting abstracts from inception through September 2018 were queried. RCTs that mention anemia, thrombocytopenia, leukopenia, neutropenia, and neutropenic fever as adverse effects were incorporated in the analysis. Mantel
A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora
Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel, and Chun Chao
Risk of developing chemotherapy-induced febrile neutropenia (FN) depends on patient-, treatment-, and disease-related characteristics. 1 In our prior investigation, several chronic comorbidities were associated with significantly increased FN
Fever and Neutropenia Clinical Practice Guidelines in Oncology
Substantial improvements have occurred in the management of infectious disease in patients with cancer. It is now unusual for patients with acute leukemia who receive their initial induction chemotherapy at a major center to die of infectious complications. Many patients will undergo further therapy that leads to prolonged periods of neutropenia without succumbing to a major infectious complication. However, managing infections in neutropenic patients remains a dynamic process, affected by the appearance of new pathogens, the emergence of antibiotic-resistant organisms, and the improved stratification of patients' infection risk. All of these factors have fostered new treatment approaches. These NCCN clinical guidelines address many of the day-to-day issues inherent in managing fever and neutropenia.
For the most recent version of the guidelines, please visit NCCN.org
Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use
Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre, and Gary H. Lyman
Background Neutropenia is a common side effect of myelosuppressive chemotherapy that increases the risk of infection, which is typically signaled by fever. When neutropenic patients develop fever (ie, febrile neutropenia [FN]), the likelihood
